In addition, CBP is a tumour-promoting molecule for some leukaemia types and is broadly studied in AML without MLLr, where aberrantly expressed CBP acetylates oncogenic transcription factors (such as MYB and CREB) to increase their transcriptional activity, contributing to leukemogenesis [35]. This evidence concerns the gene CREB1 and acute myeloid leukemia.